Summary:
Psychiatric Care and Research Center is conducting a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of CERC-301 in two different doses versus placebo, as add-on therapy in patients who are suffering from Major Depression and are having an inadequate response to their current antidepressant. This is a new antidepressant with a novel mechanism of action and will be given in two single dose administrations 7 days apart.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have an episode of depression lasting not lnoger that 2 years
•
Have a lifetime history of 2 or more episodes of depression
•
Be on either an SSRI or SNRI antidepressant
•
Have less than 50% improvement with their current antidepressant
•
Not have Schizophrenia, Bipolar disorder, or Substance Abuse within the last 6 months
Qualified Participants May Receive:
Compensation for time and travel may be possible